News

Launching a pharmaceutical product is a high-stakes undertaking. Billions may have been invested in research and development, while patent exclusivity creates a narrow window to realize value. Some reports suggest launches could rise at a 13% compound annual growth rate over the next decade, compared with 6.7% across the previous 30 years.¹ Yet one-third of US drug launches between 2012 and 2021 missed expectations.²

Most organizations understand why a therapy matters and what success should look like. The harder challenge is ensuring that strategy survives the journey into market. Audience insight must inform messaging; messaging must pass through Medical, Legal and Regulatory (MLR) review; approved content must be produced, localized and activated; field teams must be ready; and performance data must guide the next decision.

Launches rarely lose value through one dramatic failure. More often, value leaks through many small execution gaps: an unresolved evidence question, a late publication, a delayed approval, a message weakened in adaptation, an asset that arrives after the must-win moment or a local team without the tools to act. Launch day is not the beginning of execution. It is the point at which years of execution become visible.

Start with the confidence HCPs need to act

Clinical evidence is the foundation, but it is not the whole launch environment. In a proprietary qualitative HCP panel shared with HH Global, clinical trial evidence was the top-ranked information need, with 15 HCPs placing it in their top three. Guidelines and pathways followed, selected by 10. Other priorities included safety management, real-world evidence, mode of action, comparative data and implementation tools. These findings are directional rather than representative, but they expose a central launch tension: approval can precede the maturity of the information ecosystem around a therapy.

At launch, guidelines may not yet be updated. Real-world evidence may not exist. Comparative data can be unavailable, long-term safety remains uncertain, implementation tools may lag and full publication may still be pending. The information gap is therefore often practical as well as scientific. HCPs may understand what a therapy does but still need to know where it fits, how to use it and what to do when real-world complexity begins.

In an HH Global study into how HCPs prefer to receive medical education and scientific communications, panelists indicated what helped them integrate new therapies into practice with confidence. The research, which comprised 45-minute, one-to-one semi-structured interviews with 20 senior clinicians in the UK and US, highlighted practical needs such as restart timing after an adverse event, dose-reduction sequences, comparative positioning and publication timing. For novel mechanisms, crowded therapeutic areas or safety concerns, panelists sought answers to, “How do I use this?” rather than simply “What does this do?” Launch planning, therefore, should identify these confidence gaps early and assign owners to close them.

Across global life sciences launches, HH Global frequently sees commercial risk emerge not from strategy, but from the accumulation of execution gaps between approval and activation.

Design the confidence journey, not a channel list

Omnichannel planning can become a proliferation exercise: more formats, touchpoints and activity. That is not the same as progression. Each interaction should move the audience towards a more informed next step, from awareness to detailed evaluation and established use.

This requires precise audience understanding. Academic HCPs, trialists and KOLs may already know emerging data and want interpretation, comparison or difficult-case discussion. Community HCPs may need more foundational education and practical implementation support. The same therapy can therefore require different communication strategies by setting, even when the core scientific story remains the same.

Content and calls to action should map to that journey. Concise formats can support orientation; deeper evidence, evaluation; and field or peer engagement, practical questions. Later communications can respond to new evidence. Measures should show meaningful progression (e.g., quality field time, deeper evidence engagement or follow-up requests) rather than reward channel volume or passive reach.

Begin execution before approval

Speed cannot come at the expense of accuracy or completeness, but neither should approval trigger a standing start. A key launch principle is to begin years before expected approval: identify priority audiences, map stakeholders, research the market, establish the therapy’s role, plan evidence communication and prepare the content and operating model required for activation.

The panel reinforces this point. HCPs wanted more pre-launch engagement, including advisory boards during development, pre-approval intelligence from medical science liaisons, conference proceedings and breaking data and pipeline intelligence. This is not a license for promotion before approval. It is a case for compliant, medically led engagement that surfaces questions early and prepares teams for the moments that shape confidence.

A joined-up roadmap should expose dependencies across insight, medical, commercial, market access, MLR, production, localization, channels, field readiness and measurement. Clear decision rights, content priorities, review pathways and contingencies help teams respond to changes without rebuilding the launch.

Make global strategy executable locally

Global campaigns demand local understanding. Regulation influences what can be said and where; culture and infrastructure shape how communications work. Where widespread Wi-Fi cannot be assumed, mobile-first content supported by print may be more practical. Local habits can also change the balance between representative-led activity and digital tools.

The objective is governed flexibility: a clear global core designed for transcreation, localization and compliant adaptation. Regional differences should shape personas, content priorities and channel planning early enough to avoid last-minute compromise. Small changes can protect relevance without weakening consistency.

Create continuity from strategy to launch reality

HH Global provides the continuity layer across these handoffs. We connect audience understanding, content planning, production, localization, channel activation and performance visibility so strategy is not repeatedly reinterpreted. The value lies in the operating discipline that keeps people, partners, assets, approvals and markets aligned.

That continuity also supports optimization after launch. Evidence develops, HCP questions change and markets respond differently. Measurement should feed back into content and activation decisions, enabling teams to strengthen the messages, formats and interactions that build confidence while retiring activity that does not. Launch excellence is therefore not a one-off event or a fixed campaign. It is a connected system that learns.

The commercial opportunity is clear. When strategy survives execution, teams can reach must-win moments sooner, reduce avoidable rework, equip field teams more consistently and help HCPs navigate uncertainty with relevant support. When it does not, even a strong scientific and commercial proposition can arrive fragmented, late or difficult to use.

Explore how HH Global helps life sciences teams connect launch strategy to compliant, locally relevant activation, supporting them build HCP confidence from pre-approval planning through launch and beyond.

References:

2. https://www.deloitte.com/us/en/insights/industry/health-care/key-factors-for-successful-drug-launch.html